More about

Ubrogepant

News
October 28, 2024
2 min read
Save

Managing migraine pain before it begins: Understanding prodrome, early treatment options

Migraine is a complex neurological disease that disproportionately affects women during their most productive years.

News
August 29, 2024
2 min read
Save

Ubrogepant may stop migraine before headache onset

Prodromal treatment with 100 mg ubrogepant was associated with greater functionality, fewer activity limitations and a high degree of satisfaction at 24 hours in patients with migraine, according to research published in Neurology.

News
June 27, 2024
2 min read
Save

Patients with migraine report superior outcomes with ubrogepant compared to triptans

SAN DIEGO — Those with migraine who switched from an oral triptan to ubrogepant reported superior outcomes compared with patients who chose another triptan,, according to data presented at the American Headache Society Annual Scientific Meeting.

News
June 25, 2024
2 min read
Save

Sensitivity to light, sound, fatigue, neck pain most common prodromal headache symptoms

SAN DIEGO — In a small cohort of adults with headache, the most common prodromal symptoms were light and sound sensitivity, fatigue and neck pain, according to research presented at the American Headache Society Annual Scientific Meeting.

News
June 13, 2024
2 min read
Save

Concurrent atogepant, ubrogepant safe, well-tolerated for migraine at 12 weeks

SAN DIEGO — Concurrent use of atogepant for preventive treatment of episodic migraine and ubrogepant for acute migraine treatment was safe and well-tolerated at 12 weeks, according to a study.

News
April 18, 2024
1 min read
Save

Concomitant use of atogepant, ubrogepant for migraine safe over 12 weeks

DENVER — The concomitant use of atogepant for preventive and ubrogepant for acute migraine treatment was found to be safe and well-tolerated over 12 weeks, according to research presented at the American Academy of Neurology annual meeting.

News
December 29, 2023
3 min watch
Save

VIDEO: Ubrogepant prevents headache when administered in prodromal phase

Treatment with 100 mg of ubrogepant in the prodromal phase prevented development of headaches as soon as 24 hours post-dose compared with placebo, according to study co-author Peter J. Goadsby, MD, PhD, FRS.

News
November 20, 2023
2 min read
Save

Ubrogepant efficacious, well tolerated for treating migraine in prodromal phase

Treatment with 100 mg ubrogepant was effective at curbing migraine attacks when administered during the prodromal phase compared with placebo, according to research from The Lancet.

News
April 27, 2023
2 min watch
Save

VIDEO: Ubrogepant may prevent headache when dosed in prodromal phase

BOSTON — Fewer patients who took ubrogepant during the premonitory phase went on to have headache when compared with placebo, Peter Goadsby, MD, PhD, FRS, said in this Healio video at the American Academy of Neurology annual meeting.

News
November 01, 2021
1 min read
Save

Reyvow, Nurtec ODT, Ubrelvy may be alternatives for acute migraine treatment

Reyvow, Nurtec ODT and Ubrelvy were less efficacious than triptans for treating migraines, but these new pharmacologic agents correlated with fewer adverse events, according to a study published in JAMA Network Open.

View more